...
首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study.
【24h】

Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study.

机译:社区获得性和医院内腹腔感染的临床和微生物学特征:法国前瞻性,观察性EBIIA研究的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: The EBIIA (Etude epidemiologique Bacterio-clinique des Infections Intra-Abdominales) study was designed to describe the clinical, microbiological and resistance profiles of community-acquired and nosocomial intra-abdominal infections (IAIs). PATIENTS AND METHODS: From January to July 2005, patients undergoing surgery/interventional drainage for IAIs with a positive microbiological culture were included by 25 French centres. The primary endpoint was the epidemiology of the microorganisms and their resistance to antibiotics. Multivariate analysis was carried out using stepwise logistic regression to assess the factors predictive of death during hospitalization. RESULTS: Three hundred and thirty-one patients (234 community-acquired and 97 nosocomial) were included. The distribution of the microorganisms differed according to the type of infection. Carbapenems and amikacin were the most active agents in vitro against Enterobacteriaceae in both community-acquired and nosocomial infections. Against Pseudomonas aeruginosa, amikacin, imipenem, ceftazidime and ciprofloxacin were the most active agents in community-acquired infections, while imipenem, cefepime and amikacin were the most active in nosocomial cases. Against the Gram-positive bacteria, vancomycin and teicoplanin were the most active in both infections. Against anaerobic bacteria, the most active agents were metronidazole and carbapenems in both groups. Empirical antibiotic therapy adequately targeted the pathogens for 63% of community-acquired and 64% of nosocomial peritonitis. The presence of one or more co-morbidities [odds ratio (OR) = 3.17; P = 0.007], one or more severity criteria (OR = 4.90; P < 0.001) and generalized peritonitis (OR = 3.17; P = 0.006) were predictive of death. CONCLUSIONS: The principal results of EBIIA are a higher diversity of microorganisms isolated in nosocomial infections and decreased susceptibility among these strains. Despite this, the adequacy of treatment is comparable in the two groups.
机译:目的:EBIIA(腹部内细菌感染临床研究)研究旨在描述社区获得性和医院内腹内感染(IAIs)的临床,微生物学和耐药性。患者与方法:2005年1月至2005年7月,法国25个中心包括接受了微生物学阳性的IAI手术/介入引流的患者。主要终点是微生物的流行病学及其对抗生素的抗性。使用逐步逻辑回归进行多变量分析,以评估预测住院期间死亡的因素。结果:包括331例患者(234例社区获得性和97例医院内)。微生物的分布根据感染类型而不同。在社区获得性和医院感染中,碳青霉烯类和丁胺卡那霉素是体外对肠杆菌科最有效的药物。对于铜绿假单胞菌,阿米卡星,亚胺培南,头孢他啶和环丙沙星是社区获得性感染中最活跃的病原体,而亚胺培南,头孢吡肟和阿米卡星在医院内感染中最活跃。对于革兰氏阳性细菌,万古霉素和替考拉宁在两种感染中最活跃。对抗厌氧细菌,两组中活性最高的是甲硝唑和碳青霉烯。经验性抗生素治疗已充分地针对了63%的社区获得性和64%的医院性腹膜炎的病原体。一种或多种合并症的存在[比值比(OR)= 3.17; P = 0.007],一种或多种严重程度标准(OR = 4.90; P <0.001)和全身性腹膜炎(OR = 3.17; P = 0.006)可预测死亡。结论EBIIA的主要结果是在医院感染中分离出的微生物多样性更高,并且这些菌株之间的敏感性降低。尽管如此,两组的治疗充分性相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号